In the past 7 years, £17bn has been invested in healthtech innovation and the Department for Business, Energy & Industrial Strategy predicts 50% growth in the sector, globally, by 2025. Interest in healthtech is significant and growing. Healthtech entrepreneurs are increasingly avoiding the slow-moving cycle of relying on the NHS to scale-up their startups, building innovative solutions to global healthcare challenges and exploring other markets inside and outside of the UK. This is creating a significant opportunity for angel investors and the venture capital sector.
This half-day summit, organized by healthtech venture capital firm HS., took a deep dive into healthtech and provided an audience of early-stage investors with a unique opportunity to understand its complexities, some of the key emerging technologies and how to make the best investments.
Dr. James Somauroo opened the talks with the current view of the healthtech landscape before HS. founder Dr. Alex Young gave the audience HS.'s insights into how they select teams and technologies. A fireside with Dr. Jack Kreindler was as informative as it was entertaining as he detailed his incredible track record as a doctor, entrepreneur and investor and the HS. company support ecosystem was on full display after the break, with Octopus Ventures, Havas, GPDQ and Orthopaedic Research UK explaining how they add value to the HS. portfolio.
The final talk was delivered by Adam Bacon, cofounder of HS. portfolio company - Feebris as he detailed their AI/ML platform for diagnosing and predicting pneumonia and how it is being used globally to save the lives of children and the elderly.